Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesChemotherapy DrugsHCPCS hcpcs-j9245-melphalan-injection-50mg
    Ask Trek AI about this page

    HCPCS Level II J9245: Melphalan Hydrochloride Injection, 50 mg

    HCPCS Level II code J9245 denotes an injection of melphalan hydrochloride, not otherwise specified, 50 mg, typically billed for systemic chemotherapy administered via intravenous infusion or injection in an oncology clinic, hospital outpatient department, or infusion center; this descriptor identifies the drug, unit of measure (50 mg), and the clinical context for oncology drug administration claims coding.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for hcpcs J9245 policy alerts

    Get alerted when payer policies referencing J9245 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult with a hematologic malignancy such as multiple myeloma, ovarian cancer with intraperitoneal chemotherapy plan, or retinoblastoma where melphalan is indicated. The patient arrives to an oncology infusion center or hospital outpatient department for administration of J9245 (melphalan hydrochloride, 50 mg). Pre-treatment workflow includes verification of diagnosis and chemotherapy order, review of prior labs (complete blood count, renal and hepatic function), informed consent, and calculation of dose based on body surface area or protocol. Pharmacy prepares the drug under sterile technique and documents lot number and expiration; waste is recorded if partial vials are discarded. Nursing performs baseline assessment, places appropriate vascular access (peripheral IV, implanted port, or intra-arterial/intravitreal access depending on indication), initiates antiemetic prophylaxis as indicated, and administers the melphalan per protocol. Post-infusion monitoring includes vital signs, assessment for extravasation, and documentation of any immediate adverse effects. Typical sites of service are hospital outpatient infusion centers, physician offices with accredited infusion capabilities, ambulatory infusion centers, or operating rooms/interventional suites for intra-arterial or intravitreal administration. Billing uses J9245 per 50 mg vial; applicable modifiers reflect circumstances such as professional or facility billing, drug wasted, patient status, or unusual services. Documentation must include diagnosis linking to chemotherapy intent, ordered dose, lot number, administration route, site of service, and any applicable modifier rationale.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96413Chemotherapy administration, intravenous infusion technique; subsequent infusion, up to 1 hourUsed for billing the time-based IV infusion administration components when melphalan is infused as a timed infusion in the outpatient setting.
    96417Chemotherapy administration, each additional hour (list separately in addition to code for primary infusion)Billed when melphalan infusion extends beyond the first hour and additional hour increments are required.
    96415Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (up to 1 hour)When multiple sequential infusions are administered during the same visit along with melphalan.
    96365Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hourMay be used when melphalan is administered as a therapeutic infusion in settings not coded under chemotherapy-specific codes, per payer rules.
    96960Intra-arterial chemotherapy, perfusion, or regional delivery (when applicable)Billed for intra-arterial regional delivery techniques associated with melphalan administration in interventional suites.
    67028

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    56Modifier ‑56 indicates the reporting provider furnished only the preoperative management for a surgical procedure and did not perform the intraoperative or postoperative care. It is used in…- Use Modifier -56 when a provider performs only the preoperative management in a split‑care situation (one physician manages preop care while a different physician performs the intraoperative…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    363L00000X
    208000000X
    2084P0800X
    246YC3302X
    363LC1500X
    207RT0003X
    225400000X

    Related ICD-10-CM Codes

    23 rows

    ICD-10-CM CodeDescription
    C77.9Secondary and unspecified malignant neoplasm of lymph node, unspecified
    C81.90Hodgkin lymphoma, unspecified, unspecified site
    C82.90Follicular lymphoma, unspecified, unspecified site
    C83.30Diffuse large B-cell lymphoma, unspecified site
    C84.49Peripheral T-cell lymphoma, not elsewhere classified, extranodal and solid organ sites
    C85.90Non-Hodgkin lymphoma, unspecified, unspecified site
    C90.00Multiple myeloma not having achieved remission
    C90.10Plasma cell leukemia not having achieved remission
    C91.00Acute lymphoblastic leukemia not having achieved remission
    C92.00Acute myeloblastic leukemia, not having achieved remission

    Showing 1–10 of 23

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 3

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    VonvendiCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    HCPCS-J9000-DOXORUBICIN-10MG-INJECTION

    HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg

    HCPCS-J9003-LEUPROLIDE-INJECTABLE-CAMCEVI-1MG

    HCPCS Level II J9003: Leuprolide injectable (camcevi etm), 1 mg

    HCPCS-J9010-ALEMTUZUMAB-INJECTION-10MG

    HCPCS Level II J9010: Injection, alemtuzumab, 10 mg

    HCPCS-J9011-DATOPOTAMAB-DERUXTECAN-INJECTION-1MG

    HCPCS J9011: Datopotamab Deruxtecan Injection, 1 mg

    HCPCS-J9015-ALDESLEUKIN-INJECTION-SINGLE-USE-VIAL

    HCPCS Level II J9015: Aldesleukin Injection, Single-Use Vial

    HCPCS-J9017-ARSENIC-TRIOXIDE-INJECTION-1MG

    HCPCS J9017: Arsenic Trioxide Injection, 1 mg

    HCPCS-J9019-ASPARAGINASE-ERWINAZE-INJECTION-1000-IU

    HCPCS Level II J9019: Asparaginase (Erwinaze) Injection, 1,000 IU

    HCPCS-J9020-ASPARAGINASE-INJECTION-10000-UNITS

    HCPCS J9020: Asparaginase Injection, 10,000 Units

    HCPCS-J9021-ASPARAGINASE-RYLAZE-INJECTION-0-1-MG

    HCPCS Level II J9021: Injection, asparaginase (Rylaze), 0.1 mg

    HCPCS-J9022-ATEZOLIZUMAB-INJECTION-10MG

    HCPCS J9022: Injection, atezolizumab 10 mg

    Showing 1–10 of 227

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Intravitreal injection of a pharmacologic agent (separate procedure)
    Used when melphalan is administered via intravitreal injection by an ophthalmologist for ocular tumors.